En used to prevent disease24. Based on this idea, we explored the possibility that a single administration of a potent neutralizing anti-HIV MAb, in the setting of repeated low-dose (RLD) SHIV challenges, might protect for extended periods of time, thereby providing a proof of concept for periodic administration of MAb as an alternative to HIV-1 vaccination. We initially selected 3 MAbs for the RL